Weekly Psychedelic Policy Briefing: November 3, 2026

Weekly Psychedelic Policy Briefing: November 3, 2026

By Jack Gorsline

In this week’s Psychedelic Policy Briefing, Psychedelic State(s) of America founder and investigative journalist Jack Gorsline covers four defining developments across congressional drug policy reform, international clinical infrastructure, federal distribution battles, and FDA drug review and defense contracting. On Capitol Hill, Rep. Steve Cohen introduced sweeping 89-page legislation to overhaul the Controlled Substances Act, proposing to strip the DEA of scheduling authority, transfer power to public health officials, and mandate two-year reviews for psilocybin, MDMA, and ibogaine. Across the Atlantic, a new verified database mapped 487 treatment and research centers across 27 European nations, revealing stark geographic divides in legal medicine access.

In federal policy, the DEA briefly published a public directory of businesses seeking rescheduling protections before abruptly pulling it down, as Republican lawmakers pressed the Postal Service to prohibit mailing rescheduled medicines. Finally, Usona Institute filed a New Drug Application with the FDA for psilocybin in major depressive disorder, the FDA approved NRx Pharmaceuticals' preservative-free generic ketamine formulation, and the Pentagon backed sublingual ketamine wafers for battlefield trauma under a $40.95 million contract.

New Federal Bill Would Overhaul Controlled Substances Act, Shifting Scheduling to HHS and Mandating Psychedelic Reviews

U.S. Representative Steve Cohen, D-TN, has introduced landmark federal legislation to reform the Controlled Substances Act (CSA), proposing to transfer drug scheduling authority from law enforcement agencies to public health officials, deschedule marijuana, and remove regulatory hurdles to scientific research, as reported by Psychedelic State(s) of America.

Introduced in the House of Representatives as the 89-page Public Health and Research Reforms in Controlled Substances Act of 2026 (H.R. 9186), the measure represents the most comprehensive legislative effort to rewrite federal drug policy in over fifty years. Under Section 103, primary scheduling authority is transferred from the Attorney General and the Drug Enforcement Administration to the Secretary of Health and Human Services (HHS). The statutory focus shifts from general abuse potential to a clinical assessment of a substance's potential to cause substance use disorder, explicitly excluding isolated or occasional non-therapeutic use.

Section 104 replaces the current five-schedule structure with a dual-axis classification system. Each controlled substance will be assigned both a numerical schedule (Schedules I through IV) measuring risk and public health impact, and an alphabetical schedule (Schedules A through E) assessing therapeutic utility. By separating risk from medical utility, the framework allows high-risk substances with validated medical applications to be prescribed by authorized healthcare providers.

Crucially, Section 104 mandates that the HHS Secretary reevaluate 32 priority substances within two years of enactment, explicitly listing psilocybin, psilocin, MDMA, LSD, DMT, mescaline, and ibogaine, alongside fentanyl, cocaine, methamphetamine, and oxycodone. The bill includes default classification grids that automatically apply if administrative deadlines are missed. Furthermore, Section 108 transfers researcher registration authority from the DEA to HHS, allowing academic institutions to hold facility-wide research registrations and permitting scientists conducting federally funded studies or operating under FDA investigational new drug (IND) protocols to begin research 45 days after notifying HHS.

"Congressman Cohen’s bill offers a significant opportunity to move federal drug policy toward an evidence-based, public health centered focus and potentially require more proportionate responses by the DEA," said Attorney Robert Rush, founder of the Rights and Reason Project in a statement to Psychedelic State(s) of America. "A critical change in this bill is moving scheduling authority from the Department of Justice to the Department of Health and Human Services. Decisions about a substance’s risks and therapeutic benefits need to be driven by scientific and medical evidence."

International Clinical Infrastructure: New European Directory Maps 487 Verified Psychedelic and Ketamine Treatment Sites Across 27 Countries

Navigating legal access to psychedelic-assisted therapy and ketamine treatment in Europe requires sorting through 27 national regulatory systems, a dozen languages, and a mix of clinical facts and clinic marketing. On Sept. 15, a free database called PsyAccess launched to consolidate that information, publishing 487 registry-verified records across 27 European countries, as reported by Jack Gorsline for Psychedelic State(s) of America.

Operating independently within Pink Elephant Group, the directory separates active clinical care from experimental research. The 487 listings comprise 212 licensed esketamine centers, 129 clinical trial sites, 103 authorized psychedelic-assisted therapy providers, and 43 ketamine clinics. Because the 129 trial sites involve experimental research under a study protocol, the database identifies 358 providers where patients can currently receive care.

The directory illustrates sharp geographic disparities between where psychedelic medicine is legal and where it is reachable. Among the 103 authorized psychedelic-assisted therapy providers, 101 operate in Switzerland under its per-patient compassionate use framework, and two are German sites operating under an authorized psilocybin compassionate-use program (BfArM, §3 BtMG) at the Central Institute of Mental Health in Mannheim and the OVID Clinic in Berlin. None of the other 25 countries in the directory have any providers in that category, and seven nations have only a single verified provider of any kind.

Targeted clinical pathways are nevertheless expanding. In the Czech Republic, a national medical psilocybin law took effect on Jan. 1, 2026, permitting psychiatrists at approved facilities to administer synthetic psilocybin alongside psychotherapy, with clinical rollout at the National Institute of Mental Health slated for late 2026. In Southern Europe, Ambio Life Sciences operates physician-led ibogaine treatment programs and retreats in Malta and Italy, providing medically supervised care in jurisdictions where ibogaine remains unscheduled.

"As interest in psychedelic medicine grows, patients face an increasingly complex landscape spanning authorised treatments, off-label clinical practice and investigational therapies available only through research," said Dr. Rayyan Zafar, a neuropsychopharmacologist and UKRI postdoctoral fellow. "Transparent, source-linked infrastructure that helps people understand what is genuinely available is essential to patient safety."

DEA Abruptly Pulls Business Registration List as GOP Senators Move to Block Mail Delivery of Rescheduled Medicines

In an abrupt administrative maneuver, the Drug Enforcement Administration prepared and then quickly removed a dedicated webpage intended to list state-licensed cannabis businesses that applied for federal protections under the proposed Schedule III reclassification, as reported by Marijuana Moment.

The publication and subsequent deletion of the registry sparked immediate privacy and compliance concerns among state-licensed operators. Industry attorneys cautioned that publishing an agency directory of state-licensed applicants while cannabis remains federally classified in Schedule I could expose operators to unintended regulatory exposure or selective enforcement. The controversy arrives as Sen. Cory Booker, D-NJ, publicly challenged the DEA over registration questionnaires that actively interrogate business applicants about employee criminal histories, threatening operators with license denial for hiring individuals with past non-violent drug records.

Simultaneously, a pair of Republican senators sent a formal demand letter to the U.S. Postal Service urging Postmaster General Louis DeJoy to maintain an outright prohibition on mailing medical marijuana even if the substance is rescheduled to Schedule III, as reported by Marijuana Moment.

The postal delivery challenge carries profound downstream implications for the commercial rollout of prescription psychedelics. Under 21 U.S.C. § 811(j), once the FDA approves novel psychedelic formulations like COMP360 synthetic psilocybin or MDMA, commercial delivery to outpatient psychiatric clinics and certified service facilities will rely on specialized pharmaceutical distribution networks. If conservative lawmakers successfully carve out statutory bans preventing postal delivery or interstate shipment of rescheduled botanical and psychiatric medicines, emerging therapies will face severe distribution bottlenecks and regional access disparities.

Usona Files Psilocybin NDA as FDA Clears Preservative-Free Ketamine and DoD Funds Battlefield Wafers

Nonprofit research organization Usona Institute has completed its New Drug Application (NDA) submission to the FDA for its synthetic psilocybin candidate targeting major depressive disorder (MDD), Psychedelic Alpha reported Nov. 2. The filing marks the second psychedelic NDA currently under FDA review—following Resilient Pharmaceuticals' summer refiling for MDMA-assisted therapy—and sets up a tight regulatory race with Compass Pathways, which plans to complete its rolling NDA for treatment-resistant depression imminently. Both Usona and Compass hold a Commissioner's National Priority Voucher (CNPV), which targets an accelerated review decision within two months.

On the ketamine front, the FDA on Oct. 30 approved NRx Pharmaceuticals' Abbreviated New Drug Application (ANDA) for KETAFREE, a domestic, preservative-free intravenous generic ketamine formulation that omits benzethonium chloride (BZT), according to Psychedelic Alpha. Manufactured in South Carolina with Nephron Pharmaceuticals using blow-fill-seal technology to help address long-running drug shortages, the product cleared ahead of its Nov. 10 goal date, though NRx's citizen petition asking the agency to remove competing BZT-containing ketamine vials from the U.S. market remains pending.

Meanwhile, the Pentagon is backing sublingual ketamine for battlefield trauma. Under a $40.95 million Department of Defense contract awarded by the Defense Health Agency to Singapore-based iX Biopharma, the company is developing Wafermine, a fast-dissolving sublingual ketamine wafer designed to give combat medics a non-opioid option for acute moderate-to-severe pain in the field.

Daily news for curious minds.

Be the smartest person in the room. 1440 navigates 100+ sources to deliver a comprehensive, unbiased news roundup — politics, business, culture, and more — in a quick, 5-minute read. Completely free, completely factual.